20 September 2020>: Meta-Analysis
Efficacy and Toxicity of Adjuvant Therapies for High-Risk Endometrial Cancer in Stage I–III: A Systematic Review and Network Meta-Analysis
Mengyin Ao 12ABCDEF , Ting Ding 12BF , Dan Tang 12E , Mingrong Xi 12E*DOI: 10.12659/MSM.925595
Med Sci Monit 2020; 26:e925595
Table 2 League Table of pair-wise comparisons in the network meta-analysis for the relative risks (RR) of overall survival (OS), progression-free survival (PFS), distant metastasis rate, local recurrence rate, and grade III/IV late toxicities.
RR 95% CI | ||||||
---|---|---|---|---|---|---|
Pelvic RT-CT | ||||||
0.87 (0.72, 1.05) | Pelvic RT | |||||
0.93 (0.68, 1.28) | 1.08 (0.83, 1.39) | CT | ||||
0.94 (0.48, 1.83) | 1.09 (0.57, 2.05) | 1.01 (0.51, 2.01) | Pelvic RT-VBT | |||
0.82 (0.52, 1.30) | 0.95 (0.62, 1.44) | 0.88 (0.54, 1.44) | 0.87 (0.41, 1.87) | VCB/C | ||
0.77 (0.46, 1.31) | 0.89 (0.54, 1.46) | 0.83 (0.48, 1.45) | 0.82 (0.55, 1.23) | 0.94 (0.49, 1.81) | VBT | |
0.90 (0.68, 1.19) | 1.04 (0.85, 1.27) | 0.96 (0.70, 1.34) | 0.96 (0.49, 1.87) | 1.10 (0.69, 1.75) | 1.16 (0.68, 1.98) | No further treatment |
Pelvic RT-CT | ||||||
Pelvic RT | ||||||
0.80 (0.58, 1.11) | 1.04 (0.79, 1.36) | CT | ||||
0.90 (0.46, 1.75) | 1.17 (0.63, 2.18) | 1.13 (0.56, 2.24) | Pelvic RT-VBT | |||
0.82 (0.55, 1.22) | 1.06 (0.76, 1.48) | 1.02 (0.66, 1.57) | 0.91 (0.45, 1.84) | VCB/C | ||
0.74 (0.44, 1.25) | 0.96 (0.60, 1.55) | 0.93 (0.54, 1.61) | 0.83 (0.55, 1.24) | 0.91 (0.51, 1.63) | VBT | |
0.80 (0.51, 1.24) | 0.77 (0.49, 1.20) | 0.68 (0.31, 1.51) | 0.75 (0.43, 1.31) | 0.83 (0.43, 1.58) | No further treatment | |
Pelvic RT-CT | ||||||
0.85 (0.68, 1.06) | Pelvic RT | |||||
0.93 (0.64, 1.36) | 1.10 (0.81, 1.49) | CT | ||||
1.05 (0.38, 2.87) | 1.24 (0.46, 3.30) | 1.12 (0.40, 3.14) | Pelvic RT-VBT | |||
0.69 (0.33, 1.44) | 0.81 (0.40, 1.64) | 0.74 (0.34, 1.59) | 0.65 (0.33, 1.30) | VBT | ||
0.92 (0.63, 1.36) | 1.09 (0.80, 1.49) | 0.99 (0.64, 1.53) | 0.95 (0.35, 2.61) | 1.35 (0.62, 2.92) | No further treatment | |
Pelvic RT-CT | ||||||
0.51 (0.20, 1.29) | Pelvic RT | |||||
0.42 (0.15, 1.17) | 0.83 (0.54, 1.27) | CT | ||||
1.12 (0.18, 6.91) | 2.21 (0.46, 10.52) | 2.68 (0.53, 13.51) | Pelvic RT-VBT | |||
0.25 (0.06, 1.03) | 0.50 (0.17, 1.43) | 0.60 (0.19, 1.89) | VBT | |||
0.65 (0.21, 2.05) | No further treatment | |||||
Pelvic RT-CT | ||||||
1.50 (0.35, 6.36) | Pelvic RT | |||||
0.50 (0.05, 5.27) | 0.33 (0.05, 2.15) | CT | ||||
0.60 (0.03, 11.15) | 0.40 (0.03, 5.07) | 1.21 (0.05, 28.21) | Pelvic RT-VBT | |||
1.58 (0.21, 11.96) | 1.05 (0.26, 4.35) | 3.18 (0.30, 33.12) | 2.64 (0.14, 48.35) | VCB/C | ||
1.49 (0.15, 15.28) | 1.00 (0.16, 6.16) | 3.00 (0.22, 40.78) | 2.49 (0.42, 14.63) | 0.94 (0.09, 9.50) | VBT | |
5.87 (0.68, 50.32) | 3.91 (0.80, 19.20) | 9.79 (0.49, 196.16) | 3.71 (0.44, 31.25) | 3.93 (0.35, 44.15) | No further treatment |